With 13 years of experience and an outstanding record of performance, the HIV Prevention Trials Network (HPTN) Laboratory Center (LC) is optimally positioned to support the HPTN in 2013 and beyond. As part of the HPTN Leadership Group, the LC will help shape the network's scientific agenda. The HPTN LC will oversee laboratory activities at study sites;perform Quality Control/Quality Assurance (QA/QC) and specialized testing for HPTN protocols;evaluate and validate assays for use in HPTN protocols;develop novel assays to achieve study objectives;and perform ancillary studies related to HIV prevention. The HPTN LC has comprehensive QA/QC, Virology, and Pharmacology Cores, with Support Laboratories in other key areas (Sexually Transmitted Diseases, Microbiology, Immunology, and Toxicology). The HPTN LC has extensive experience supporting HIV prevention trials in the United States, South America, Asia, and Africa and has led efforts to harmonize laboratory procedures across networks and in other groups. The HPTN LC has supported HPTN protocols evaluating behavioral, biomedical, and structural interventions for HIV prevention, often delivered in combination in a wide range of settings and non-traditional venues. This includes observational, Phase I, Phase II and Phase III studies, with interventions delivered to HIV uninfected individuals, HIV-infected individuals, couples, cohorts, and communities. HPTN study populations include adolescents, women, men who have sex with men, serodiscordant couples, injection drug users, and individuals with acute HIV infection, with some trials enrolling >50,000 participants.
The Specific Aims of the HPTN LC are:
Aim 1 : To provide leadership, expertise, and laboratory support to the HPTN;
Aim 2 : To support site laboratories and ensure the quality of HPTN laboratory results;
Aim 3 : To advance HIV prevention science through assay development and biomedical research. A strong and effective LC is particularly important in the HPTN because of the vast international scope, diversity, and complexity of HIV prevention trials. This award will enable the HPTN to continue its mission to identify effective strategies for HIV prevention that will help end the HIV/AIDS epidemic.
The goal of HIV Prevention Trials Network (HPTN) is to identify effective strategies for HIV prevention. The HPTN Laboratory Center (LC) is part of the HPTN leadership group. HPTN LC investigators will oversee laboratory testing performed at study sites, analyze samples collected in HPTN studies, develop novel laboratory assays, and perform laboratory-related research relevant to HIV prevention.
|Wada, Nikolas I; Bream, Jay H; MartÃnez-Maza, Otoniel et al. (2016) Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study. Clin Infect Dis 63:984-90|
|Dize, Laura; Barnes Jr, Perry; Barnes, Mathilda et al. (2016) Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium by nucleic acid amplification assays. Diagn Microbiol Infect Dis 86:131-5|
|Ranganathan, Meghna; Heise, Lori; Pettifor, Audrey et al. (2016) Transactional sex among young women in rural South Africa: prevalence, mediators and association with HIV infection. J Int AIDS Soc 19:20749|
|Golin, Carol E; Haley, Danielle F; Wang, Jing et al. (2016) Post-traumatic Stress Disorder Symptoms and Mental Health over Time among Low-Income Women at Increased Risk of HIV in the U.S. J Health Care Poor Underserved 27:891-910|
|Gaydos, Charlotte A; Jett-Goheen, Mary; Barnes, Mathilda et al. (2016) Self-testing for Trichomonas vaginalis at home using a point-of-care test by women who request kits via the Internet. Sex Health :|
|McKay, Heather S; Bream, Jay H; Margolick, Joseph B et al. (2016) Host factors associated with serologic inflammatory markers assessed using multiplex assays. Cytokine 85:71-9|
|Cohen, Myron S; Chen, Ying Q; McCauley, Marybeth et al. (2016) Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 375:830-9|
|Fogel, Jessica M; Clarke, William; Kulich, Michal et al. (2016) Antiretroviral drug use in a cross-sectional population survey in Africa: NIMH Project Accept (HPTN 043). J Acquir Immune Defic Syndr :|
|Hendrix, Craig W; Andrade, Adriana; Bumpus, NamandjÃ© N et al. (2016) Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses 32:32-43|
|Landovitz, Raphael J; Kofron, Ryan; McCauley, Marybeth (2016) The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS 11:122-8|
Showing the most recent 10 out of 147 publications